viewImmuPharma PLC

Corporate Update

/**/ link{ color: blue }visited{ color: #954F72 } .k{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.k{}p.aq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.ao{font-family:"Calibri","sans-serif"; color:black}p.ar{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}span.am{font-family:"Calibri","sans-serif";color:black}p.as{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.at{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.au{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: justify}p.av{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white} p.aw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; line-height: 106%; text-align: justify}span.af{font-family:"Calibri","sans-serif"}p.ax{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify;punctuation-wrap: hanging;text-autospace:ideograph-other}p.ay{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify}span.ad{font-family:"Calibri","sans-serif";color:#2D2D2D}p.az{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify;background: white}p.ba{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-bottom: 18.75pt; text-align: justify}span.z{font-family:"Calibri","sans-serif";background:white}table.bb{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.m{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt} p.bc{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.bd{width:18.0cm;border-collapse:collapse}td.w{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.be{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.u{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.v{font-family: "Calibri","sans-serif"}span.t{font-family: "Calibri","sans-serif";color:black}p.bf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}p.bg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}p.bh{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify} td.p{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.o{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";} /**/
RNS Number : 1178Y
Immupharma PLC
07 May 2019

                                                                                                                                                                                 7 May 2019


ImmuPharma PLC

("ImmuPharma" or the "Company")




ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities.




Lupuzor™ is the Company's late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial in 2018, ImmuPharma continues to look at opportunities which the Board believes over the longer term have the potential of bringing Lupuzor™ to market. As part of this strategy, the Company confirms that it continues to engage with potential corporate partners as well as consulting with regulatory advisors on potential pathways to market. Whilst these activities continue the commencement of the Managed Access Program for Lupuzor™ will be postponed until the Company has further clarification on these activities.

Lupuzor™ Extension Study

The Lupuzor™ open label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in Q2 2019.

Merger of Elro Pharma and Ureka

ImmuPharma's subsidiaries Elro Pharma Sarl and Ureka Sarl, both based in France, are focussing on unique technologies: the Nucant cancer programme (Elro) and the peptide platform (Ureka).

As previously announced, the Company has been exploring its options to licence, divest or 'spin-off' the technologies of both of these subsidiaries to unlock their future potential and enhance value to shareholders.

Following an internal review, the Company's intention is to merge these two subsidiaries, in order to create a stronger combined company with a platform technology together with a drug candidate in clinical development, with a view to securing external investment either from private equity or through a public listing on a European stock exchange. This in turn would allow ImmuPharma PLC to focus on Lupuzor™ and the overall P140 platform for different autoimmune indications

Further details will be announced in due course.

Incanthera Limited


Further to the announcement of 1 April 2019, all discussions with Incanthera on the Nucant cancer programme and broader collaboration discussions have now terminated.



Final Results


ImmuPharma will provide a further update on its operations and strategy in its Final results for the year ended 31 December 2018, which are expected to be announced by the end of this month.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")


For further information please contact:


ImmuPharma PLC (www.immupharma.com)

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer


Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496


SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev


Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes


SI Capital (Joint Broker)

Nick Emerson


+44 (0) 203 368 8974




+44 (0) 203 815 8880



+44 (0) 1483 413500














This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: ImmuPharma PLC

Price: 14.4

Market: AIM
Market Cap: £24.1 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

on 16/12/19